MedTrace Logo

Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P

NCT01919944 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-06-03

No results posted yet for this study

Summary

The purpose of this study is to test whether VLY-686 can prevent or reduce the itch and dermatological reaction observed after healthy volunteers are injected with Substance P in comparison with placebo.

Conditions

Interventions

DRUG

VLY-686

capsules containing either 10 mg or 50 mg VLY-686

DRUG

Placebo

Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule

Sponsors & Collaborators

Principal Investigators

  • Milko Radicioni, MD · Cross Research SA

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01919944 on ClinicalTrials.gov